ProBioGen's GlymaxX(R) ADCC Enhancement Technology Used by Bet...
BERLIN, January 3, 2019 /PRNewswire-AsiaNet/ -- Bispecific Antibody for Cancer Treatment Optimized by GlymaxX(R) TechnologyProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed mil...
Read more https://view-release/?pr-id=76936